FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany
118 -
PO:03:034 | Inhibition of Radiographic Progression with Bimekizumab Treatment Observed in bDMARD-Naïve Patients with Active Psoriatic Arthritis at 2 Years: Results from a Phase 3 Study and its Open-Label Extension Laura C Coates1, M Elaine Husni2, Mitsumasa Kishimoto3, Proton Rahman4, Philipp Sewerin5, Enrique R Soriano6, Barbara Ink7, Rajan Bajracharya7, Jason Coarse8, Philip J Mease9, Emanuela Mazzola10, Peter Nash11 | 1NDORMS, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust Oxford, United Kingdom; 2Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Cleveland, USA; 3Department of Nephrology and Rheumatology, Kyorin University School of Medicine Tokyo, Japan; 4Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Memorial University of Newfoundland St. Johns, Canada; 5Rheumazentrum Ruhrgebiet, University Hospital of the Ruhr University Bochum Herne Germany; 6Hospital Italiano de Buenos Aires and University Institute Hospital Italiano de Buenos Aires Buenos Aires, Argentina; 7UCB Slough, United Kingdom; 8UCB Morrisville, USA; 9Department of Rheumatology, Providence-Swedish Medical Center and University of Washington Seattle, USA; 10UCB Milan, Italy; 11School of Medicine, Griffith University, Brisbane, Australia
130 -
PO:15:217 | Improved efficacy and safety outcomes in patients with systemic lupus erythematosus treated with belimumab vs. immunosuppressants, in addition to antimalarials and glucocorticoids: a post-hoc summary of five phase 3 trials Mariele Gatto1, Karen H. Costenbader2, Andreas Schwarting3, Julia Hn Harris4, Ciara O'Shea5, Roger A. Levy6, Andrea Doria7 | 1Centro Accademico Reumatologia, Dipartimento Scienze Cliniche Biologiche, Università degli Studi Torino, Osp. Mauriziano, Italy; 2Brigham and Women's Hospital, Divisione di Reumatologia, Infiammazione e Immunità, Harvard Medical School, Boston, MA, USA; 3Università Johannes Gutenberg di Mainz, Centro medico universitario, Germany; 4GSK, Immunologia Biostatistica London, UK; 5GSK, Global Medical Affairs Reumatologia, Dublin, Ireland; 6GSK, Global Medical Affairs Collegeville, PA, USA; 7Divisione di Reumatologia, Dipartimento di Medicina, Università di Padova, Italy
222
1 - 3 of 3 items
